Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G. Rusakiewicz S, et al. Among authors: thurlimann b. Eur J Cancer. 2024 Mar;200:113535. doi: 10.1016/j.ejca.2024.113535. Epub 2024 Jan 24. Eur J Cancer. 2024. PMID: 38309015
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A. Thürlimann B, et al. Eur J Cancer. 1997 Jun;33(7):1017-24. doi: 10.1016/s0959-8049(97)00105-6. Eur J Cancer. 1997. PMID: 9376181 Clinical Trial.
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roché H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G. Thürlimann B, et al. Eur J Cancer. 1997 Oct;33(11):1767-73. doi: 10.1016/s0959-8049(97)00283-9. Eur J Cancer. 1997. PMID: 9470830 Clinical Trial.
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thürlimann B, Simoncini E, Fey M, Price K, Senn HJ. Pagani O, et al. Among authors: thurlimann b. Eur J Cancer. 1998 Apr;34(5):632-40. doi: 10.1016/s0959-8049(97)10036-3. Eur J Cancer. 1998. PMID: 9713266 Clinical Trial.
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A. Colleoni M, et al. Among authors: thurlimann b. J Clin Oncol. 2000 Feb;18(3):584-90. doi: 10.1200/JCO.2000.18.3.584. J Clin Oncol. 2000. PMID: 10653873
Identifying breast cancer patients at high risk for bone metastases.
Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam CM. Colleoni M, et al. Among authors: thurlimann b. J Clin Oncol. 2000 Dec 1;18(23):3925-35. doi: 10.1200/JCO.2000.18.23.3925. J Clin Oncol. 2000. PMID: 11099322
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.
Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Cortes-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A; International Breast Cancer Study Group. Colleoni M, et al. Among authors: thurlimann b. J Clin Oncol. 2001 Nov 1;19(21):4141-9. doi: 10.1200/JCO.2001.19.21.4141. J Clin Oncol. 2001. PMID: 11689582 Clinical Trial.
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam CM, Schmoor C, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Crivellari D, Beyerle C, Neumann RL, Goldhirsch A; International Breast Cancer Study Group; German Breast Cancer Study Group. Colleoni M, et al. Among authors: thurlimann b. Br J Cancer. 2002 Jun 5;86(11):1705-14. doi: 10.1038/sj.bjc.6600334. Br J Cancer. 2002. PMID: 12087454 Free PMC article. Clinical Trial.
234 results